You are here

Tecentriq

Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC

Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC

BioSpace

non-squamous cell non-small cell lung cancer

Flag link:

Tecentriq could be first front-line SCLC therapy approved in two decades

Tecentriq could be first front-line SCLC therapy approved in two decades

BioCentury

extensive-stage small cell lung cancer

Flag link:

One more shot at slowing Keytruda’s first-line lung cancer domination

One more shot at slowing Keytruda’s first-line lung cancer domination

EP Vantage

Flag link:

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Fierce Pharma

Flag link:

Roche’s Tecentriq gets fast review in triple negative breast cancer

Roche’s Tecentriq gets fast review in triple negative breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Benefit of Roche's Tecentriq looks limited in breast cancer

Benefit of Roche's Tecentriq looks limited in breast cancer

Biopharma Dive

triple negative breast cancer

Flag link:

Real threat to Opdivo’s small-cell chances will come from elsewhere

Real threat to Opdivo’s small-cell chances will come from elsewhere

EP Vantage

Bristol-Myers Squibb

Small-Cell Lung Cancer

Flag link:

Tecentriq sets the bar in small-cell lung cancer

Tecentriq sets the bar in small-cell lung cancer

Biopharma Dive

Small-Cell Lung Cancer

Flag link:

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

Endpoints

Flag link:

US agency to rule on Tecentriq’s most important use

US agency to rule on Tecentriq’s most important use

EP Vantage

non-squamous non-small cell lung cancer

Flag link:

FDA Limits the Use of Tecentriq and Keytruda

FDA Limits the Use of Tecentriq and Keytruda

RAPS.org

metastatic urothelial cancer

Flag link:

Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival

Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival

Endpoints

triple negative breast cancer

Flag link:

With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche?

With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche?

Fierce Pharma

clinical trials

small cell lung cancer

Flag link:

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

Biopharma Dive

Flag link:

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

ASCO18: Tecentriq scores again in lung cancer, but Keytruda looms in background

Biopharma Dive

advanced squamous non-small cell lung cancer

Flag link:

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

CP Wire

clinical trials

Flag link:

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors

Flag link:

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Endpoints

non-squamous non-small cell lung cancer

Bristol-Myers Squibb

Flag link:

Pages